Chordia and others, including SBI Investment, reported a change in equity ownership from 21.98% to 20.95%.

Filing Party: SBI Investment Co., Ltd. Filing Date and Time: February 6, 2026, 16:31 Document Filed: Amendment Report (Cover Page = Amendment Report 7) Reporting Obligation Trigger Date: January 30, 2026 Reason for Filing Amendment Report: A decrease of 1% or more in the holding ratio of stock certificates, etc., and a decrease of 1% or more in the holding ratio of individual stock certificates, etc. Issuer: <190A>Chordia Therapeutics Co., Ltd.

Jiji PressFeb 6 02:34 ET

Chordia Therapeutics' Major Shareholder Diluted Below 10% After Warrant Exercises

TipRanksFeb 3 00:22 ET

Funds are likely to flow into emerging markets amid firm economic conditions.

[Emerging Market Stock Strategy] The emerging market is expected to show a solid performance today. On the 27th in the U.S. stock market, the Dow Jones Industrial Average fell by 408.99 points (-0.83%) to close at 49,003.41, reversing from its previous gains. The Dow opened lower and remained weak throughout the session, significantly influenced by the sharp decline in one of its constituent stocks, UnitedHealth Group (UNH). Early morning earnings announcements were met with disappointment, compounded by a smaller-than-expected increase in a 27-year insurance payment proposal by the U.S. government, which triggered profit-taking.

Fisco JapanJan 27 18:20 ET

Chordia and SBI Investment, among others, reported a change in equity ownership from 23.13% to 21.98%.

Filing Party: SBI Investment Co., Ltd. Filing Date and Time: January 23, 2026, 15:38 Document Filed: Amendment Report (Cover Page = Amendment Report 6) Reporting Obligation Trigger Date: January 16, 2026 Reason for Filing Amendment Report: Decrease of 1% or more in the proportion of shares held, decrease of 1% or more in the proportion of shares held individually, and changes of 1% or more in the breakdown Issuer: <190A>Chordia Ther

Jiji PressJan 23 01:41 ET

Chordia---1Q is promoting research and development of five pipelines centered around rogocekib.

Chordia Therapeutics <190A> announced its financial results for the first quarter of the fiscal year ending August 2026 (September-November 2025) on the 14th. The company reported no business revenue (same as the previous year), an operating loss of 306 million yen (compared to a loss of 624 million yen in the same period last year), an ordinary loss of 294 million yen (compared to a loss of 615 million yen), and a quarterly net loss of 295 million yen (compared to a loss of 616 million yen). The company is developing CLK inhibitor CTX-712, with the international nonproprietary name rogocekib (hereinafter,

Fisco JapanJan 15 01:38 ET

Five companies have disclosed their earnings, while seven companies have postponed their announcements in the Q1 and Q3 financial results released on the 14th – Continuation of Corporate Assumptions.

In the earnings briefings for the first and third quarters disclosed on January 14, five listed companies included a note regarding the going concern assumption due to the presence of events or conditions that raise significant doubts about their ability to continue as a going concern. The companies in question are as follows: ▽ Fiscal Year Ending February 2026, Third Quarter: Aqua Line <6173>, Rapine <8143> ▽ Fiscal Year Ending August 2026, First Quarter: ANAP <3189>, abc <8783>, Bunkyo-do HD <9978>. Additionally, there are events or conditions that raise significant doubts about the ability to continue as a going concern.

Jiji PressJan 14 20:19 ET